Journal articles: 'MR-Guided Radiation Therapy'

1

van der Heide, Uulke A. "MR-guided radiation therapy." Physica Medica 32 (September 2016): 175. http://dx.doi.org/10.1016/j.ejmp.2016.07.284.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Greenwood, Bernadette Marie, Stuart May, and John Francis Feller. "Transrectal MR-guided laser focal therapy of recurrent prostate cancer in a patient post-proton therapy: A case study." Journal of Clinical Oncology 34, no. 3_suppl (January 20, 2016): e298-e298. http://dx.doi.org/10.1200/jco.2016.34.3_suppl.e298.

Full text

Abstract:

e298 Background: Prostate cancer is commonly managed with radical prostatectomy (RP) or radiation therapy (RT). 20-40% of men undergoing RP experience biochemical recurrence (BCR) before 10 years. 30-50% or those receiving RT experience BCR. Treatment options for these men are limited and include: salvage radiation, close surveillance, androgen deprivation therapy (ADT), or participation in a clinical trial. Our IRB-approved study evaluated the use of transrectally delivered, MR-guided laser focal therapy with real-time MR thermometry for the treatment of recurrent prostate cancer. Methods: 63 y.o. patient treated September, 2014 with MR-guided laser focal salvage therapy for locally recurrent prostate cancer, Gleason score 4+5 involving the transition zone far anteriorly at the base level measuring 1.4 x 1.1 x 1.3 cm. The patient was originally diagnosed with Gleason score 4+3 adenocarcinoma of the prostate by MR ultrasound fusion biopsy in 2012 and subsequently underwent treatment with proton beam radiation therapy. Results: MR-guided biopsy of the prostate August, 2014 confirmed the presence of locally recurrent PCa. Before MR-guided laser focal therapy, the biochemical recurrence was documented with an elevated serum PSA equal to 5.7. The 3- and 6-month post laser focal therapy serum PSA levels were 0.5. It reached a nadir of 0.3 at one year following the laser ablation. Patient had negative 6-month follow-up MR-guided biopsy of treatment region and remains on active surveillance Conclusions: Following proton beam radiation therapy, transrectal MR-guided laser focal therapy achieved oncologic control at 12 months post-treatment. Clinical trial information: 02243033.

APA, Harvard, Vancouver, ISO, and other styles

3

Adjepong, Dennis. "MR-Guided Radiation Therapy: Clinical Applications & Experiences." Surgery: Current Trends and Innovations 4, no. 3 (June 19, 2020): 1–5. http://dx.doi.org/10.24966/scti-7284/100038.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Stanescu, T., J. Balter, T. Nyholm, and J. Lagendijk. "TU-A-BRF-01: MR Guided Radiation Therapy." Medical Physics 41, no. 6Part26 (May 29, 2014): 446. http://dx.doi.org/10.1118/1.4889233.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Stanescu, T., T. Tadic, and D. A. Jaffray. "Commissioning of an MR-Guided Radiation Therapy System." International Journal of Radiation Oncology*Biology*Physics 90, no. 1 (September 2014): S94—S95. http://dx.doi.org/10.1016/j.ijrobp.2014.05.495.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Gensanne, D., P. Gouel, P. Decaze, A. Edet-Sanson, F. Callonnec, F. Douvrin, A. Benyoucef, B. Dubray, I. Gardin, and P. Vera. "24 PET/CT-MR guided radiation therapy workflow." Physica Medica 56 (December 2018): 15. http://dx.doi.org/10.1016/j.ejmp.2018.09.037.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Богачев, Ю. В., А. В. Никитина, В. В. Фролов, and В. И. Чижик. "МРТ-управляемая терапия." Журнал технической физики 90, no. 9 (2020): 1487. http://dx.doi.org/10.21883/jtf.2020.09.49680.22-20.

Full text

Abstract:

Magnetic resonance (MR) theranostics is a new direction of modern medicine, in which high diagnostic capabilities of magnetic resonance methods are combined with therapeutic effects on various organs of physical fields of various nature. The features and clinical applications of MR-theranostics methods and equipment, including MRI-guided high-intensity focused ultrasound surgery (tumor ablation), MRI-guided radiation (x-ray) therapy, MRI-guided proton therapy, and MRI-guided radiofrequency therapy, are considered.

APA, Harvard, Vancouver, ISO, and other styles

8

Stanescu, T., K. Wachowicz, and D. Jaffray. "WE-G-214-04: MR Simulation Environment for MR-Guided Radiation Therapy." Medical Physics 38, no. 6Part33 (June 2011): 3831. http://dx.doi.org/10.1118/1.3613425.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Parikh, Neil R., Percy P. Lee, Steven S. Raman, Minsong Cao, James Lamb, Marguerite Tyran, Walter Chin, et al. "Time-Driven Activity-Based Costing Comparison of CT-Guided Versus MR-Guided SBRT." JCO Oncology Practice 16, no. 11 (November 2020): e1378-e1385. http://dx.doi.org/10.1200/jop.19.00605.

Full text

Abstract:

PURPOSE: Magnetic resonance–guided radiation therapy (MRgRT) has recently become commercially available, offering the opportunity to accurately image and target moving tumors as compared with computed tomography-guided radiation therapy (CTgRT) systems. However, the costs of delivering care with these 2 modalities remain poorly described. With localized unresectable hepatocellular carcinoma as an example, we were able to use time-driven activity-based costing to determine the cost of treatment on linear accelerators with CTgRT compared with MRgRT. MATERIALS AND METHODS: Process maps, informed via interviews with departmental personnel, were created for each phase of the care cycle. Stereotactic body radiation therapy was delivered at 50 Gy in 5 fractions, either with CTgRT using fiducial placement, deep inspiration breath-hold (DIBH) with real-time position management, and volumetric-modulated arc therapy, or with MRgRT using real-time tumor gating, DIBH, and static-gantry intensity-modulated radiation therapy. RESULTS: Direct clinical costs were $7,306 for CTgRT and $8,622 for MRgRT comprising personnel costs ($3,752 v $3,603), space and equipment costs ($2,912 v $4,769), and materials costs ($642 v $250). Increased MRgRT costs may be mitigated by forgoing CT simulation ($322 saved) or shortening treatment to 3 fractions ($1,815 saved). Conversely, adaptive treatment with MRgRT would result in an increase in cost of $529 per adaptive treatment. CONCLUSION: MRgRT offers real-time image guidance, avoidance of fiducial placement, and ability to use adaptive treatments; however, it is 18% more expensive than CTgRT under baseline assumptions. Future studies that elucidate the magnitude of potential clinical benefits of MRgRT are warranted to clarify the value of using this technology.

APA, Harvard, Vancouver, ISO, and other styles

10

Zhang, L., F. F. Yin, and J. Cai. "A Multi-Source Adaptive MR Image Fusion Technique for MR-Guided Radiation Therapy." International Journal of Radiation Oncology*Biology*Physics 102, no. 3 (November 2018): e552. http://dx.doi.org/10.1016/j.ijrobp.2018.07.1537.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Wang, Wei, Charles L. Dumoulin, Akila N. Viswanathan, Zion T. H. Tse, Alireza Mehrtash, Wolfgang Loew, Isaiah Norton, et al. "Real-time active MR-tracking of metallic stylets in MR-guided radiation therapy." Magnetic Resonance in Medicine 73, no. 5 (June 5, 2014): 1803–11. http://dx.doi.org/10.1002/mrm.25300.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Finazzi, Tobias, Miguel A. Palacios, Cornelis J. A. Haasbeek, Marjan A. Admiraal, Femke O. B. Spoelstra, Anna M. E. Bruynzeel, Berend J. Slotman, Frank J. Lagerwaard, and Suresh Senan. "Stereotactic MR-guided adaptive radiation therapy for peripheral lung tumors." Radiotherapy and Oncology 144 (March 2020): 46–52. http://dx.doi.org/10.1016/j.radonc.2019.10.013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Luo, Dong, Andrew Johnson, Xinning Wang, Hao Li, Bernadette O. Erokwu, Sarah Springer, Jason Lou, et al. "Targeted Radiosensitizers for MR-Guided Radiation Therapy of Prostate Cancer." Nano Letters 20, no. 10 (August 26, 2020): 7159–67. http://dx.doi.org/10.1021/acs.nanolett.0c02487.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Jaffray, D. A., M. Carlone, S. Breen, M. Milosevic, C. Menard, T. Stanescu, A. Rink, H. Alasti, M. Sweitzer, and J. Winter. "Development of a Novel Platform for MR-Guided Radiation Therapy." International Journal of Radiation Oncology*Biology*Physics 87, no. 2 (October 2013): S13. http://dx.doi.org/10.1016/j.ijrobp.2013.06.039.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Lagerwaard, F., A. Bruynzeel, S. Tetar, S. S. Oei, C. Haasbeek, B. J. Slotman, S. Senan, O. Bohoudi, and M. Palacios. "Stereotactic MR-Guided Adaptive Radiation Therapy (SMART) for Prostate Cancer." International Journal of Radiation Oncology*Biology*Physics 99, no. 2 (October 2017): E681—E682. http://dx.doi.org/10.1016/j.ijrobp.2017.06.2246.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Yadav, Poonam, Abdelbasset Hallil, Dinesh Tewatia, David A. P. Dunkerley, and Bhudatt Paliwal. "MOSFET dosimeter characterization in MR‐guided radiation therapy (MRgRT) Linac." Journal of Applied Clinical Medical Physics 21, no. 1 (December 18, 2019): 127–35. http://dx.doi.org/10.1002/acm2.12799.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Tatsui, Claudio E., Sun-Ho Lee, Behrang Amini, Ganesh Rao, Dima Suki, Marilou Oro, Paul D. Brown, et al. "Spinal Laser Interstitial Thermal Therapy." Neurosurgery 79, suppl_1 (December 1, 2016): S73—S82. http://dx.doi.org/10.1227/neu.0000000000001444.

Full text

Abstract:

Abstract BACKGROUND: Although surgery followed by radiation effectively treats metastatic epidural compression, the ideal surgical approach should enable fast recovery and rapid institution of radiation and systemic therapy directed at the primary tumor. OBJECTIVE: To assess spinal laser interstitial thermotherapy (SLITT) as an alternative to surgery monitored in real time by thermal magnetic resonance (MR) images. METHODS: Patients referred for spinal metastasis without motor deficits underwent MR-guided SLITT, followed by stereotactic radiosurgery. Clinical and radiological data were gathered prospectively, according to routine practice. RESULTS: MR imaging-guided SLITT was performed on 19 patients with metastatic epidural compression. No procedures were discontinued because of technical difficulties, and no permanent neurological injuries occurred. The median follow-up duration was 28 weeks (range 10-64 weeks). Systemic therapy was not interrupted to perform the procedures. The mean preoperative visual analog scale scores of 4.72 (SD ± 0.67) decreased to 2.56 (SD ± 0.71, P = .043) at 1 month and remained improved from baseline at 3.25 (SD ± 0.75, P = .021) 3 months after the procedure. The preoperative mean EQ-5D index for quality of life was 0.67 (SD ± 0.07) and remained without significant change at 1 month 0.79 (SD ± 0.06, P = .317) and improved at 3 months 0.83 (SD ± 0.06, P = .04) after SLITT. Follow-up MR imaging after 2 months revealed significant decompression of the neural component in 16 patients. However, 3 patients showed progression at follow-up, 1 was treated with surgical decompression and stabilization and 2 were treated with repeated SLITT. CONCLUSION: MR-guided SLITT can be both a feasible and safe alternative to separation surgery in carefully selected cases of spinal metastatic tumor epidural compression.

APA, Harvard, Vancouver, ISO, and other styles

18

Pomp, Jacquelien, Bram van Asselen, Robbert H. A. Tersteeg, Aryan Vink, Rutger J. Hassink, Niels P. van der Kaaij, Guido E. E. H. L. van Aarnhem, and Joost J. C. Verhoeff. "Sarcoma of the Heart Treated with Stereotactic MR-Guided Online Adaptive Radiation Therapy." Case Reports in Oncology 14, no. 1 (March 12, 2021): 453–58. http://dx.doi.org/10.1159/000513623.

Full text

Abstract:

We present the first case in the literature of a patient with a histology-proven intimal sarcoma of the heart, recurrent after surgery, treated with stereotactic MR-guided online adaptive radiation therapy on an MR-Linac machine. The treatment was feasible and well tolerated. The CT scan 6 months after the last treatment showed stable disease.

APA, Harvard, Vancouver, ISO, and other styles

19

Sim, Austin J., Russell F. Palm, Kirby B. DeLozier, Vladimir Feygelman, Kujtim Latifi, Gage Redler, Iman R. Washington, Evan J. Wuthrick, and Stephen A. Rosenberg. "MR-guided stereotactic body radiation therapy for intracardiac and pericardial metastases." Clinical and Translational Radiation Oncology 25 (November 2020): 102–6. http://dx.doi.org/10.1016/j.ctro.2020.10.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Tetar, S. U., A. Bruynzeel, S. S. Oei, S. Senan, A. M. van der Wel, B. J. Slotman, A. J. M. van den Eertwegh, R. J. A. van Moorselaar, and F. Lagerwaard. "MR-guided Stereotactic Body Radiation Therapy for Large Primary Kidney Tumors." International Journal of Radiation Oncology*Biology*Physics 108, no. 3 (November 2020): e892. http://dx.doi.org/10.1016/j.ijrobp.2020.07.499.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Liang, E., E. D. Morris, J. Vono, L. Bazan, M. Lu, A. Modh, and C. Glide-Hurst. "Coupling Continuous Positive Airway Pressure (CPAP) and MR-guided Radiation Therapy." International Journal of Radiation Oncology*Biology*Physics 108, no. 3 (November 2020): S169. http://dx.doi.org/10.1016/j.ijrobp.2020.07.942.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Aldridge, K., E. D. Morris, A. I. Ghanem, S. Zhu, B. Movsas, I. J. Chetty, and C. Glide-Hurst. "Potential for Sensitive Cardiac Substructure Sparing Using MR-guided Radiation Therapy." International Journal of Radiation Oncology*Biology*Physics 105, no. 1 (September 2019): E728. http://dx.doi.org/10.1016/j.ijrobp.2019.06.915.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Sim, A. J., R. F. Palm, K. DeLozier, V. Feygelman, K. Latifi, G. Redler, I. Washington, E. J. Wuthrick, and S. A. Rosenberg. "MR-Guided Stereotactic Body Radiation Therapy for Intracardiac and Pericardial Metastases." International Journal of Radiation Oncology*Biology*Physics 108, no. 3 (November 2020): e362-e363. http://dx.doi.org/10.1016/j.ijrobp.2020.07.2361.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Parikh, Parag, Daniel Low, Olga L. Green, and Percy P. Lee. "Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for locally advanced pancreatic cancer." Journal of Clinical Oncology 38, no. 4_suppl (February 1, 2020): TPS786. http://dx.doi.org/10.1200/jco.2020.38.4_suppl.tps786.

Full text

Abstract:

TPS786 Background: Standard dose radiation therapy has been unsuccessful in inoperable pancreatic cancer; with a negative study (LAP07) for conventional chemoradiation and dropping of the stereotactic body radiation therapy arm in Alliance A021501. Recently, reports of using high dose ablative radiation therapy has been associated with increased survival in retrospective studies. Moreover, technological advances with MRI-guided radiation therapy offer improved targeting and the ability to change the radiation delivery on a daily fashion; allowing ablative radiation doses over one week. However, it is not clear whether this can be done safely on a multiinstitutional basis. Methods: We are conducting the largest prospective study of ablative radiation therapy in pancreatic cancer. The study is a single arm, multi-institutional phase II, industry sponsored study to investigate the safety and efficacy of Stereotactic, MR guided, on-table-Adaptive Radiation Therapy (SMART). Eligibility criteria include locally advanced and borderline resectable pancreatic cancer patients with ECOG PS of 0 or 1; who have non-metastatic disease after a minimum of 3 months of any systemic therapy; including investigational agents. Patients will receive MR-guided radiation therapy to a dose of 50 Gy / 5 fractions; with maximum tumor coverage delivered each fraction that allows keeping the gastrointestinal organs at risk to a dose of 33 Gy or less. Primary endpoint is grade 3 of higher gastrointestinal toxicity at 90 days. Secondary endpoints are overall survival at 2 years, distant progression free survival at 6 months, and changes in patient related quality of life at 3 and 12 months. Target sample size was calculated to show at a significance level 0.05, a reduction of the toxicity rate to 8% or lower by using SMART compared with 15.8%, the toxicity rate of conventionally delivered chemoradiation at a power level 0.8. Given an expected 15% drop-out, the enrollment goal is 133. Descriptive statistics will be used for secondary objectives. The study opened in January, 2019 and is currently opened at 4 centers; with other US and international sites pending. Sponsored by Viewray, Inc. Clinical trial information: NCT03621644.

APA, Harvard, Vancouver, ISO, and other styles

25

Przybysz, D., T. R. Mazur, H. M. Gach, C. G. Robinson, M. C. Roach, O. L. Green, S. Mutic, J. D. Bradley, and B. Cai. "Stereotactic Body Radiation Therapy for Thoracic Malignancies: An Analysis of MR-Guided Radiation Therapy Gating Tracking Accuracy." International Journal of Radiation Oncology*Biology*Physics 102, no. 3 (November 2018): e665-e666. http://dx.doi.org/10.1016/j.ijrobp.2018.07.1801.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Chen, X., S. Oh, M. S. Hwang, D. Lee, R. Fuhrer, A. V. Kirichenko, P. B. Renz, and J. W. Sohn. "Dosimetric Assessment for Real-Time Anatomical Motion during MR-Guided Radiation Therapy by MR-LINAC." International Journal of Radiation Oncology*Biology*Physics 114, no. 3 (November 2022): e589. http://dx.doi.org/10.1016/j.ijrobp.2022.07.2271.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Romesser, Paul B., Neelam Tyagi, and Christopher H. Crane. "Magnetic Resonance Imaging-Guided Adaptive Radiotherapy for Colorectal Liver Metastases." Cancers 13, no. 7 (April 1, 2021): 1636. http://dx.doi.org/10.3390/cancers13071636.

Full text

Abstract:

Technological advances have enabled well tolerated and effective radiation treatment for small liver metastases. Stereotactic ablative radiation therapy (SABR) refers to ablative dose delivery (>100 Gy BED) in five fractions or fewer. For larger tumors, the safe delivery of SABR can be challenging due to a more limited volume of healthy normal liver parenchyma and the proximity of the tumor to radiosensitive organs such as the stomach, duodenum, and large intestine. In addition to stereotactic treatment delivery, controlling respiratory motion, the use of image guidance, adaptive planning and increasing the number of radiation fractions are sometimes necessary for the safe delivery of SABR in these situations. Magnetic Resonance (MR) image-guided adaptive radiation therapy (MRgART) is a new and rapidly evolving treatment paradigm. MR imaging before, during and after treatment delivery facilitates direct visualization of both the tumor target and the adjacent normal healthy organs as well as potential intrafraction motion. Real time MR imaging facilitates non-invasive tumor tracking and treatment gating. While daily adaptive re-planning permits treatment plans to be adjusted based on the anatomy of the day. MRgART therapy is a promising radiation technology advance that can overcome many of the challenges of liver SABR and may facilitate the safe tumor dose escalation of colorectal liver metastases.

APA, Harvard, Vancouver, ISO, and other styles

28

Castelluccia, Alessandra, Pierpaolo Mincarone, Maria Rosaria Tumolo, Saverio Sabina, Riccardo Colella, Antonella Bodini, Francesco Tramacere, Maurizio Portaluri, and Carlo Giacomo Leo. "Economic Evaluations of Magnetic Resonance Image-Guided Radiotherapy (MRIgRT): A Systematic Review." International Journal of Environmental Research and Public Health 19, no. 17 (August 30, 2022): 10800. http://dx.doi.org/10.3390/ijerph191710800.

Full text

Abstract:

Objectives: This review systematically summarizes the evidence on the economic impact of magnetic resonance image-guided RT (MRIgRT). Methods: We systematically searched INAHTA, MEDLINE, and Scopus up to March 2022 to retrieve health economic studies. Relevant data were extracted on study type, model inputs, modeling methods and economic results. Results: Five studies were included. Two studies performed a full economic assessment to compare the cost-effectiveness of MRIgRT with other forms of image-guided radiation therapy. One study performed a cost minimization analysis and two studies performed an activity-based costing, all comparing MRIgRT with X-ray computed tomography image-guided radiation therapy (CTIgRT). Prostate cancer was the target condition in four studies and hepatocellular carcinoma in one. Considering the studies with a full economic assessment, MR-guided stereotactic body radiation therapy was found to be cost effective with respect to CTIgRT or conventional or moderate hypofractionated RT, even with a low reduction in toxicity. Conversely, a greater reduction in toxicity is required to compete with extreme hypofractionated RT without MR guidance. Conclusions: This review highlights the great potential of MRIgRT but also the need for further evidence, especially for late toxicity, whose reduction is expected to be the real added value of this technology.

APA, Harvard, Vancouver, ISO, and other styles

29

Mein, S., L. Rankine, D. Miles, T. Juang, B. Cai, A. Curcuru, S. Mutic, et al. "How feasible is remote 3D dosimetry for MR guided Radiation Therapy (MRgRT)?" Journal of Physics: Conference Series 847 (May 2017): 012056. http://dx.doi.org/10.1088/1742-6596/847/1/012056.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Ménard, Cynthia, Douglas Iupati, Julia Publicover, Jenny Lee, Jessamine Abed, Gerald O’Leary, Anna Simeonov, et al. "MR-guided Prostate Biopsy for Planning of Focal Salvage after Radiation Therapy." Radiology 274, no. 1 (January 2015): 181–91. http://dx.doi.org/10.1148/radiol.14122681.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Li, Winnie, Jennifer Dang, Vickie Kong, Tim Craig, Jeff Winter, Peter Chung, and Andrew Bayley. "204: Bladder Volume Variability During Mr-Guided Prostate Stereotactic Body Radiation Therapy." Radiotherapy and Oncology 150 (September 2020): S87. http://dx.doi.org/10.1016/s0167-8140(20)31096-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Botman, R., S. U. Tetar, M. A. Palacios, B. J. Slotman, F. J. Lagerwaard, and A. M. E. Bruynzeel. "The clinical introduction of MR-guided radiation therapy from a RTT perspective." Clinical and Translational Radiation Oncology 18 (September 2019): 140–45. http://dx.doi.org/10.1016/j.ctro.2019.04.019.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Ghanem, Ahmed, Simeng Zhu, Eric Morris, Benjamin Movsas, Indrin Chetty, and Carri Glide-Hurst. "Quantification of Cardiac Substructure Inter-fraction Displacement for MR-guided Radiation Therapy." International Journal of Radiation Oncology*Biology*Physics 108, no. 2 (October 2020): E17—E18. http://dx.doi.org/10.1016/j.ijrobp.2020.02.505.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Detappe, A., S. Kunjachan, L. Sancey, V. Motto-Ros, O. Tillement, and R. Berbeco. "WE-FG-BRA-07: Theranostic Nanoparticles Improve Clinical MR-Guided Radiation Therapy." Medical Physics 43, no. 6Part41 (June 2016): 3824–25. http://dx.doi.org/10.1118/1.4957907.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Bruynzeel, A., F. Lagerwaard, S. Tetar, S. S. Oei, C. Haasbeek, O. Bohoudi, B. J. Slotman, M. Meijerink, S. Senan, and M. Palacios. "Stereotactic MR-Guided Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Tumors." International Journal of Radiation Oncology*Biology*Physics 99, no. 2 (October 2017): S125. http://dx.doi.org/10.1016/j.ijrobp.2017.06.293.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Rosenberg, Stephen A., Lauren E. Henke, Narek Shaverdian, Kathryn Mittauer, Andrzej P. Wojcieszynski, Craig R. Hullett, Mitchell Kamrava, et al. "A Multi-Institutional Experience of MR-Guided Liver Stereotactic Body Radiation Therapy." Advances in Radiation Oncology 4, no. 1 (January 2019): 142–49. http://dx.doi.org/10.1016/j.adro.2018.08.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Cai, Bin, Harold Li, Deshan Yang, Vivian Rodriguez, Austen Curcuru, Yuhe Wang, Jie Wen, Rojano Kashani, Sasa Mutic, and Olga Green. "Performance of a multi leaf collimator system for MR-guided radiation therapy." Medical Physics 44, no. 12 (October 19, 2017): 6504–14. http://dx.doi.org/10.1002/mp.12571.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Bohoudi, Omar, Anna M. E. Bruynzeel, Shyama Tetar, Ben J. Slotman, Miguel A. Palacios, and Frank J. Lagerwaard. "Dose accumulation for personalized stereotactic MR-guided adaptive radiation therapy in prostate cancer." Radiotherapy and Oncology 157 (April 2021): 197–202. http://dx.doi.org/10.1016/j.radonc.2021.01.022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Nosrati, Reyhaneh, Moti Paudel, Ananth Ravi, Ana Pejovic-Milic, Gerard Morton, and Greg J. Stanisz. "Potential applications of the quantitative susceptibility mapping (QSM) in MR-guided radiation therapy." Physics in Medicine & Biology 64, no. 14 (July 16, 2019): 145013. http://dx.doi.org/10.1088/1361-6560/ab2623.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

McDonald, BA, HJ Lee, and GS Ibbott. "Evaluation of a lung-equivalent gel dosimeter for MR image-guided radiation therapy." Journal of Physics: Conference Series 1305 (August 2019): 012012. http://dx.doi.org/10.1088/1742-6596/1305/1/012012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Zips, D. "SP-0112 First clinical experience and future directions of MR-guided radiation therapy." Radiotherapy and Oncology 133 (April 2019): S59. http://dx.doi.org/10.1016/s0167-8140(19)30532-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Zhu, S., A. I. Ghanem, E. D. Morris, and C. Glide-Hurst. "Inter-Fraction Cardiac Substructure Displacement Quantified by Magnetic Resonance (MR)-Guided Radiation Therapy." International Journal of Radiation Oncology*Biology*Physics 108, no. 3 (November 2020): e324. http://dx.doi.org/10.1016/j.ijrobp.2020.07.774.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Jiang, N., M. Tyran, M. Cao, A. Raldow, J. M. Lamb, D. Low, M. L. Steinberg, and P. Lee. "Retrospective Evaluation of Decision-Making for Pancreatic Stereotactic MR-Guided Adaptive Radiation Therapy." International Journal of Radiation Oncology*Biology*Physics 102, no. 3 (November 2018): S209—S210. http://dx.doi.org/10.1016/j.ijrobp.2018.07.120.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Fischer-Valuck, Benjamin Walker, and Jeff M. Michalski. "Magnetic resonance image-guided radiation therapy (MR-IGRT) for the treatment of prostate cancer: Initial clinical experience and patient selection." Journal of Clinical Oncology 34, no. 2_suppl (January 10, 2016): 156. http://dx.doi.org/10.1200/jco.2016.34.2_suppl.156.

Full text

Abstract:

156 Background: Magnetic resonance image-guided radiation therapy (MR-IGRT) has been implemented at our institution since 2014. We report on the initial clinical experience and patient selection in treating prostate cancer utilizing the first commercially-implemented MR-IGRT system. Methods: A total of 13 patients with prostate cancer have been treated with intensity-modulated radiation therapy (IMRT) using an MR-IGRT system. Of those treated, 6 patients received definitive radiation therapy (RT) for low, intermediate or high risk prostate cancer, 5 patients were treated with salvage RT after biochemical failure following surgery, and 1 patient was treated for the boost portion of definitive RT. Results: Patients were selected for MR-IGRT based on various clinical decisions. Four patients had co-morbidities requiring anticoagulation for which fiducial marker placement was contraindicated and soft tissue visualization via MR imaging was thought to be beneficial for daily set-up. Three patients were referred from outside institutions with concerns of radiation dose to the small bowel, and daily MR monitoring of bowel anatomy could be performed with plans for treatment adaptation if anatomy changed. One patient had received prior RT for rectal cancer and dose to organs at risk was of concern. The remainder of patients were post-operative salvage cases selected based on physician concern of accurate and reproducible daily localization with fiducial markers alone. Daily volumetric MR was monitored with the ability for treatment adaptation should small bowel dose increase, and no treatment changes were required. For all cases, onboard sagittal cine MR was visually monitored for bladder and target motion, and qualitative evaluation demonstrated no significant intra-fraction motion. Conclusions: MR-IGRT provides unique advantages when fiducial markers are contraindicated or when daily visualization of dose to the small bowel or other organs at risk is required to monitor and potentially prevent normal tissue toxicity. Clinical trials are in development to formally evaluate MR-IGRT for the treatment of intact and salvage prostate cancer.

APA, Harvard, Vancouver, ISO, and other styles

45

Wu, Tao, and Joel P. Felmlee. "A quality control program for MR-guided focused ultrasound ablation therapy." Journal of Applied Clinical Medical Physics 3, no. 2 (March 2002): 162–67. http://dx.doi.org/10.1120/jacmp.v3i2.2584.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Sheybani, Natasha Diba, Alexandra R. Witter, Timothy N. Bullock, and Richard J. Price. "MR image-guided focused ultrasound immune modulation for glioma therapy." Journal of Immunology 200, no. 1_Supplement (May 1, 2018): 178.26. http://dx.doi.org/10.4049/jimmunol.200.supp.178.26.

Full text

Abstract:

Abstract Glioblastoma (GB) is the most common and malignant brain tumor. Despite standard treatment with surgery, radiation and chemotherapy, its diffuse nature and proclivity for recurrence renders it largely intractable. Immunotherapy (ITx) approaches (e.g. anti-PD1) may hold promise for treating GB; however, the blood-brain (BBB) and blood-tumor (BTB) barriers hinder delivery of systemically administered ITx drugs. A potential approach to enhancing ITx delivery is MRI-guided focused ultrasound (FUS), a non-invasive technique that, when combined with concomitant systemic injection of microbubbles (MB), can transiently disrupt the BBB/BTB and mechanically perturb the tumor microenvironment. Here, we investigate whether localized BBB/BTB disruption with FUS+MB enhances anti-tumor immune responses and inhibits tumor growth, as a prelude to eventual combination with immune checkpoint blockade. One week after FUS+MB (peak negative acoustic pressure=0.6 MPa) treatment of a murine glioma model stably transfected with luciferase (GL261-luc2), CD86 mean fluorescence intensity on dendritic cells (DC) increased ~3-fold in deep cervical lymph nodes, intratumoral CD4+ T cells doubled, and intratumoral CD8+ T cells increased by ~17% (by flow cytometry). Serial bioluminescence imaging of tumors revealed significant reduction in total photon flux as early as 6 days following FUS+MB (p=0.0106), indicating tumor growth inhibition. We conclude that FUS+MB can promote DC maturity and potentially mediate adaptive immunity against glioma, independent of drug delivery. Ongoing studies entail combining FUS+MB with anti-PD-1 delivery to evaluate whether an allied treatment approach can promote an even more robust anti-glioma response.

APA, Harvard, Vancouver, ISO, and other styles

47

Alexander, Michael J., Antonio A. F. DeSalles, and Uwamie Tomiyasu. "Multiple radiation-induced intracranial lesions after treatment for pituitary adenoma." Journal of Neurosurgery 88, no. 1 (January 1998): 111–15. http://dx.doi.org/10.3171/jns.1998.88.1.0111.

Full text

Abstract:

✓ This 53-year-old man presented with a syncopal episode 31 years after undergoing craniotomy and external-beam radiation for a pituitary macroadenoma. A gadolinium-enhanced magnetic resonance (MR) image of the brain demonstrated a 2.5-cm enhancing mass in the right caudate region that had not been seen on previous studies. A stereotactically guided biopsy procedure was performed to obtain specimens from the mass, which were consistent with ependymoma. The MR image also revealed two additional lesions that appeared to be within the radiation fields: a right temporal meningioma and a left frontal cavernous malformation. A review of the literature found three previous reports in which ependymomas presented after radiation therapy.

APA, Harvard, Vancouver, ISO, and other styles

48

Lavigne, Danny, Sweet Ping Ng, Brian O’Sullivan, Phuc Felix Nguyen-Tan, Edith Filion, Laurent Létourneau-Guillon, Clifton D. Fuller, and Houda Bahig. "Magnetic Resonance-Guided Radiation Therapy for Head and Neck Cancers." Current Oncology 29, no. 11 (October 31, 2022): 8302–15. http://dx.doi.org/10.3390/curroncol29110655.

Full text

Abstract:

Despite the significant evolution of radiation therapy (RT) techniques in recent years, many patients with head and neck cancer still experience significant toxicities during and after treatments. The increased soft tissue contrast and functional sequences of magnetic resonance imaging (MRI) are particularly attractive in head and neck cancer and have led to the increasing development of magnetic resonance-guided RT (MRgRT). This approach refers to the inclusion of the additional information acquired from a diagnostic or planning MRI in radiation treatment planning, and now extends to online high-quality daily imaging generated by the recently developed MR-Linac. MRgRT holds numerous potentials, including enhanced baseline and planning evaluations, anatomical and functional treatment adaptation, potential for hypofractionation, and multiparametric assessment of response. This article offers a structured review of the current literature on these established and upcoming roles of MRI for patients with head and neck cancer undergoing RT.

APA, Harvard, Vancouver, ISO, and other styles

49

Kuczmarska-Haas, A., P. Yadav, H. B. Musunuru, J. S. Witt, D. M. Francis, S. A. Rosenberg, H. C. Ko, et al. "Assessing Radiation Induced Liver Damage Following MR-Guided Stereotactic Body Radiation Therapy (SBRT): Challenging Current Dose Constraints." International Journal of Radiation Oncology*Biology*Physics 102, no. 3 (November 2018): e25. http://dx.doi.org/10.1016/j.ijrobp.2018.07.506.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Chen, Xinfeng, Ergun Ahunbay, Eric S. Paulson, Guangpei Chen, and X. Allen Li. "A daily end‐to‐end quality assurance workflow for MR‐guided online adaptive radiation therapy on MR‐Linac." Journal of Applied Clinical Medical Physics 21, no. 1 (December 4, 2019): 205–12. http://dx.doi.org/10.1002/acm2.12786.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'MR-Guided Radiation Therapy'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles